• Explore /
  • Poster
  • / Camrelizumab plus apatinib after progression on immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma (CAP 02 Re-challenge): A single-arm multicenter, phase II trial.

Camrelizumab plus apatinib after progression on immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma (CAP 02 Re-challenge): A single-arm multicenter, phase II trial.

Abstract Poster

Authors

null

Xiangrui Meng

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Xiangrui Meng , Junsheng Wang , Jin Xia , Tao Wu , Zhiquan Luo , Yong-Gui Hong , Ping Lu , Yanzhen Guo , Yinghua Ji , Min Zhang , Liuzhong Yang , Peng Cheng , Wenchang Liang , Zhengzheng Shan , Qingxia Fan , Feng Wang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03736863

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 364)

DOI

10.1200/JCO.2024.42.3_suppl.364

Abstract #

364

Poster Bd #

H6

Abstract Disclosures

Similar Posters

First Author: Feng Wang

First Author: Feng Wang

First Author: Jie Shen

First Author: Huaying Wang